公开(公告)号：TR200102162T2

公开(公告)日：2001-12-21

申请号：TR200102162

申请日：2000-01-25

Applicant: ABBOTT LAB

Inventor： BUNNELLE WILLIAM H ,  CRISTINA DANIELA BARLOCCO ,  DAANEN JEROME F ,  DART MICHAEL J ,  MEYER MICHAEL D ,  RYTHER KEITH B ,  SCHRIMPF MICHAEL R ,  SIPPY KEVIN B ,  TOUPENCE RICHARD B

IPC: A61K31/00 ,  A61K31/407 ,  A61K31/4355 ,  A61K31/4365 ,  A61K31/439 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/502 ,  A61P9/10 ,  A61P15/10 ,  A61P25/00 ,  A61P25/02 ,  A61P25/06 ,  A61P25/08 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  C07D401/08 ,  C07D471/08 ,  C07D487/08 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00 ,  A61K31/395

Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein: V is selected from the group consisting of a covalent bond and CH2; W is selected from the group consisting of a covalent bond, CH2 and CH2CH2; X is selected from the group consisting of a covalent bond and CH2; Y is selected from the group consisting of a covalent bond, CH2 and CH2CH2; Z is selected from the group consisting of CH2 and CH2CH2, and CH2CH2CH2; L1 is selected from the group consisting of a covalent bond and (CH2)n; n is 1-5; R1 is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), and (l); R2 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, aminoalkyl, aminocarbonylalkyl, benzyloxycarbonyl, cyanoalkyl, dihydro-3-pyridinylcarbonyl, hydroxy, hydroxyalkyl, phenoxycarbonyl, and -NH2; are useful for controlling synaptic transmission in mammal.

公开(公告)号：HU0001110A2

公开(公告)日：2001-04-28

申请号：HU0001110

申请日：1997-12-10

Applicant: ABBOTT LAB

Inventor： ARNERIC STEPHEN P ,  BAI HAO ,  DART MICHAEL J ,  EHRLICH PAUL P ,  HOLLADAY MARK W ,  LIN NAN-HORNG ,  LYNCH JOHN K ,  OR YAT SUN ,  RYTHER KEITH B ,  SULLIVAN JAMES P ,  WASICAK JAMES T

IPC: A61P25/04 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/485 ,  A61P25/28 ,  A61P29/00 ,  C07D205/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14

Abstract: The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula (I) or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula (I) which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.

公开(公告)号：NO992705A

公开(公告)日：1999-08-03

申请号：NO992705

申请日：1999-06-03

Applicant: ABBOTT LAB

Inventor： HOLLADAY MARK W ,  ARNERIC STEPHEN P ,  BAI HAO ,  DART MICHAEL J ,  LIN NAN-HORNG ,  LYNCH JOHN K ,  OR YAT SUN ,  RYTHER KEITH B ,  SULLIVAN JAMES P ,  WASICAK JAMES T ,  EHRLICH PAUL P

IPC: A61P25/04 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/485 ,  A61P25/28 ,  A61P29/00 ,  C07D205/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  A61K31/44

CPC classification number: C07D401/12 ,  A61K31/4427 ,  A61K31/485 ,  C07D205/04 ,  Y02P20/55 ,  A61K2300/00

公开(公告)号：AU6318898A

公开(公告)日：1998-09-09

申请号：AU6318898

申请日：1998-02-05

Applicant: ABBOTT LAB

Inventor： WASICAK JAMES T ,  GARVEY DAVID S ,  HOLLADAY MARK W ,  LIN NAN-HORNG ,  RYTHER KEITH B

IPC: A61P25/04 ,  A61K31/422 ,  A61K31/4439 ,  A61K31/4725 ,  A61P25/00 ,  A61P43/00 ,  C07D487/04 ,  A61K31/44

Abstract: 7a-Substituted hexahydro-1H-pyrrolizine compounds having the formula wherein A is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to selectively control synaptic transmission in mammals.

公开(公告)号：MX9800776A

公开(公告)日：1998-04-30

申请号：MX9800776

申请日：1996-07-25

Applicant: ABBOTT LAB

Inventor： ELLIOTT RICHARD L ,  RYTHER KEITH B ,  HOLLADAY MARK W ,  WASICAK JAMES T ,  DAANEN JEROME F

IPC: A61K31/00 ,  A61K31/435 ,  A61K31/4353 ,  A61K31/4355 ,  A61P9/00 ,  A61P25/00 ,  A61P25/30 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D491/044 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00

Abstract: Novedosos compuestos de éteres heterocíclicos que tienen la formula (I) en donde A, m, R, X, Y1, Y2 y Y3 son definidos específicamente, los cuales sonutiles en controlar selectivamente la transmision sináptica química, composiciones farmacéuticas terapéuticamente efectivas de los mismos; y uso de dichas composiciones para controlar selectivamente la transmision sináptica en mamíferos.

公开(公告)号：AU2010202299A1

公开(公告)日：2010-06-24

申请号：AU2010202299

申请日：2010-06-02

Applicant: ABBOTT LAB

Inventor： BASHA ANWER ,  BUNNELLE WILLIAM H ,  DART MICHAEL J ,  GALLAGHER MEGAN E ,  JI JIANGUO ,  MORTELL KATHLEEN H ,  NERSESIAN DIANA L ,  PACE JENNIFER M ,  RYTHER KEITH B ,  SCHRIMPF MICHAEL R ,  TIETJE KARIN R

IPC: C07D471/04 ,  A61K31/435 ,  A61P25/00 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08

Abstract: Compounds of formula (I) Z-Ar 1 -Ar 2 wherein Z is a diazabicyclic amine, Ar 1 is a 5- or 6-membered aromatic ring, and Ar 2 is selected from the group consisting of an unsubstituted or substituted 5-or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazoyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by ±7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

公开(公告)号：CA2273917C

公开(公告)日：2010-05-25

申请号：CA2273917

申请日：1997-12-10

Applicant: ABBOTT LAB

Inventor： HOLLADAY MARK W ,  ARNERIC STEPHEN P ,  BAI HAO ,  DART MICHAEL J ,  LIN NAN-HORNG ,  LYNCH JOHN K ,  OR YAT SUN ,  RYTHER KEITH B ,  SULLIVAN JAMES P ,  WASICAK JAMES T ,  EHRLICH PAUL P

IPC: A61P25/04 ,  C07D401/12 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/485 ,  A61P25/28 ,  A61P29/00 ,  C07D205/04 ,  C07D401/14 ,  C07D405/14

Abstract: The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula (I) or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula (I) which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.

公开(公告)号：CA2285263C

公开(公告)日：2009-03-10

申请号：CA2285263

申请日：1998-04-10

Applicant: ABBOTT LAB

Inventor： DAANEN JEROME F ,  LI YIHONG ,  RYTHER KEITH B ,  HOLLADAY MARK W ,  ELLIOTT RICHARD L ,  LIN NAN-HORNG ,  WASICAK JAMES T ,  DART MICHAEL J ,  HE YUN

IPC: C07D491/048 ,  A61K31/4355 ,  A61K31/4365 ,  A61P25/00 ,  A61P43/00 ,  C07D491/04 ,  C07D495/04 ,  C07D519/00

Abstract: Novel heterocyclic ether compounds having formula (I) wherein A, m, R, X, Y1 , Y2 and Y3 are specifically defined, which are useful in selectively controlling chemical synaptic transmission; therapeutically- effective pharmaceutical compositions thereof; and use of said compositions to selectively control synaptic transmission in mammals.

公开(公告)号：PL200427B1

公开(公告)日：2009-01-30

申请号：PL35206600

申请日：2000-05-15

Applicant: ABBOTT LAB

Inventor： SCHRIMPF MICHAEL R ,  SIPPY KEVIN B ,  DAANEN JEROME F ,  RYTHER KEITH B ,  JI JIANGUO

IPC: C07D401/04 ,  C07D491/048 ,  A61K31/00 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/4545 ,  A61K45/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  C07D495/04

公开(公告)号：CA2227695C

公开(公告)日：2008-02-12

申请号：CA2227695

申请日：1996-07-25

Applicant: ABBOTT LAB

Inventor： RYTHER KEITH B ,  ELLIOTT RICHARD L ,  DAANEN JEROME F ,  WASICAK JAMES T ,  HOLLADAY MARK W ,  DART MICHAEL J

IPC: C07D491/048 ,  A61K31/00 ,  A61K31/435 ,  A61K31/4353 ,  A61K31/4355 ,  A61K31/495 ,  A61K31/53 ,  A61P9/00 ,  A61P25/00 ,  A61P25/30 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D491/044 ,  C07D495/04 ,  C07D519/00

Abstract: Novel heterocyclic ether compounds having the formula (I) wherein A, m, R, X , Y1, Y2 and Y3 are specifically defined, which are useful in selectively controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions thereof; and use of said compositions to selectively control synaptic transmission in mammals.